GLSHQ (Gelesis Holdings) Total Receivables: $9.56 Mil (As of Jun. 2023)


What is Gelesis Holdings Total Receivables?

Gelesis Holdings GLSHQ -99.00% Total Receivables is $9.56 Mil as of Jun. 2023.

Gelesis Holdings's Total Receivables for the quarter that ended in Jun. 2023 was $9.56 Mil.

Gelesis Holdings Total Receivables Related Terms

Gelesis Holdings Total Receivables Historical Data

* Premium members only.

The historical data trend for Gelesis Holdings's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelesis Holdings Total Receivables Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
Total Receivables
16.33 8.45

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.11 9.46 8.45 14.11 9.56

Gelesis Holdings Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $9.56 Mil mean?
Gelesis Holdings (GLSHQ) has a Total Receivables of $9.56 Mil as of Jun. 2023. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Gelesis Holdings and its competitors.
Is Gelesis Holdings' Total Receivables too high?
Gelesis Holdings' current Total Receivables is $9.56 Mil.
How does Gelesis Holdings' Total Receivables compare to RBSH and PPCB?
Gelesis Holdings' Total Receivables of $9.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Gelesis Holdings and its competitors. Gelesis Holdings's current Total Receivables is $9.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelesis Holdings stock overvalued right now?
Gelesis Holdings (GLSHQ) has a current Total Receivables of $9.56 Mil. The current Total Receivables is $9.56 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Gelesis Holdings (GLSHQ), the current Total Receivables is $9.56 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelesis Holdings Business Description

Address 501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.